Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taxus in Japan

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific launches Taxus Liberté paclitaxel-eluting stent after gaining reimbursement from Japan's National Health Insurance System March 2. Taxus Liberté was approved by the Ministry of Health, Labor and Welfare Jan. 28, and is the "only second-generation drug-eluting stent in Japan," according to Boston Scientific (1"The Gray Sheet" Feb. 2, 2009, p. 15). The firm has pointed to Liberté as an example of accelerating approval times in Japan, where the regulatory pathway has historically been difficult to navigate for device makers. Abbott filed for Japanese approval of the Xience V everolimus-eluting stent in June. Boston Sci also markets its first-generation Taxus Express2 stent in Japan. Liberté was introduced in the U.S. last fall (2"The Gray Sheet" July 28, 2008, p. 10)

You may also be interested in...



Boston Scientific Predicts 2009 Will Be The Year Guidant Buy Proves Wise

Boston Scientific CEO Jim Tobin says 2009 will be the year when his company's gamble on cardiac rhythm management begins to pay off the way it hoped when it entered the CRM business by buying Guidant in 2006

Boston Scientific Plans 2008 Post-Warning Letter Interventional Launches

Boston Scientific plans to launch four new interventional cardiology products in 2008 after resolving a two-and-a-half-year-old company-wide FDA warning letter

Sun's Halol Site Faces FDA Action

FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.

Topics

UsernamePublicRestriction

Register

MT027197

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel